TRABD2B Antibody, Biotin conjugated
Description
Introduction to TRABD2B Antibody, Biotin Conjugated
TRABD2B (UniProt ID: A6NFA1), also known as TIKI2, is a metalloprotease that cleaves specific Wnt proteins (e.g., WNT3A, WNT5) to inhibit Wnt signaling, a pathway critical for embryonic development and tissue homeostasis . The biotin-conjugated TRABD2B antibody facilitates targeted detection in assays such as ELISA, immunohistochemistry (IHC), and western blot (WB) .
Immunogen and Reactivity
The antibody targets residues 195–405 of TRABD2B, a region critical for its metalloprotease activity . Cross-reactivity is confirmed exclusively in human samples, with no reported reactivity in other species . The biotin conjugation method (likely ZBPA-based, as per general best practices ) ensures specificity without nonspecific binding to albumin or other proteins .
Applications in Research
-
ELISA: Direct antigen capture in sandwich assays, with detection via streptavidin-HRP conjugates .
-
Western Blot: Detects TRABD2B at ~65–79 kDa in human cell lines (DU 145, HT-29, HeLa) .
-
Immunohistochemistry: Potential for tissue-specific localization studies, pending protocol optimization .
Recommended Dilutions
Validation Data
-
Western Blot: Strong bands observed at 65–79 kDa in DU 145 (prostate cancer), HT-29 (colon cancer), and HeLa (cervical cancer) cells, confirming specificity .
-
IHC Compatibility: Biotinylation methods like ZBPA minimize background staining compared to non-specific conjugation techniques (e.g., Lightning-Link) .
Research Limitations
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research indicates that TRABD2B is upregulated in renal cell carcinoma tissues and plays an oncogenic role in this type of cancer. PMID: 26942462
- Studies have focused on the structural prediction and identification of the active site residues of human TRABD2B. PMID: 26631728
- Evidence suggests that reduced expression of TRABD2B family proteins in osteosarcoma may contribute to the progression of this disease. Restoring the expression of these proteins has been shown to inhibit osteosarcoma growth. PMID: 24771064
- Clinical trials are investigating the association between TRABD2B and various diseases, as well as its interactions with environmental factors. (HuGE Navigator) PMID: 20379614
